MX2010012290A - Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. - Google Patents

Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.

Info

Publication number
MX2010012290A
MX2010012290A MX2010012290A MX2010012290A MX2010012290A MX 2010012290 A MX2010012290 A MX 2010012290A MX 2010012290 A MX2010012290 A MX 2010012290A MX 2010012290 A MX2010012290 A MX 2010012290A MX 2010012290 A MX2010012290 A MX 2010012290A
Authority
MX
Mexico
Prior art keywords
phenyl
oxo
methyl
carboxamide
yloxy
Prior art date
Application number
MX2010012290A
Other languages
English (en)
Spanish (es)
Inventor
Angela Coxon
Isabelle Dussault
Darrin Beaupre
Teresa L Burgess
Paula Kaplan-Lefko
Anthony J Polverino
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2010012290A publication Critical patent/MX2010012290A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2010012290A 2008-05-14 2009-05-14 Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. MX2010012290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12775308P 2008-05-14 2008-05-14
PCT/US2009/044034 WO2009140549A1 (en) 2008-05-14 2009-05-14 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2010012290A true MX2010012290A (es) 2011-02-21

Family

ID=40908799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012290A MX2010012290A (es) 2008-05-14 2009-05-14 Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.

Country Status (7)

Country Link
US (2) US20110104161A1 (enExample)
EP (1) EP2288383A1 (enExample)
JP (1) JP5699075B2 (enExample)
AU (1) AU2009246263B2 (enExample)
CA (1) CA2723617A1 (enExample)
MX (1) MX2010012290A (enExample)
WO (1) WO2009140549A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
KR101353763B1 (ko) 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2010045344A1 (en) * 2008-10-17 2010-04-22 Genentech, Inc. Combination therapy comprising a c-met antagonist and a vegf antagonist
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
EP2588107A1 (en) * 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2621482A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
WO2012042421A1 (en) * 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
KR20120100027A (ko) 2011-03-02 2012-09-12 한국생명공학연구원 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물
SG192273A1 (en) 2011-03-29 2013-09-30 Eisai R&D Man Co Ltd Method for producing phenoxypyridine derivative
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2726088B1 (en) * 2011-06-29 2019-01-02 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
CA2866321A1 (en) * 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
EP2864291B1 (en) 2012-06-26 2016-10-05 Bayer Pharma Aktiengesellschaft N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
EP2879677B1 (en) * 2012-07-28 2017-06-14 Calitor Sciences, LLC Substituted pyrazolone compounds and methods of use
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
JP6267619B2 (ja) * 2014-09-30 2018-01-24 学校法人近畿大学 慢性骨髄性白血病の治療用組成物
WO2016104617A1 (ja) * 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
US9920033B2 (en) * 2015-11-14 2018-03-20 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
KR102571911B1 (ko) 2017-01-26 2023-08-28 오노 야꾸힝 고교 가부시키가이샤 퀴놀린 유도체의 에탄술폰산염
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning
AU2018259078B2 (en) 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
IL296790B1 (en) * 2020-03-30 2026-07-01 Hutchmed Ltd Amide compounds and their uses
WO2021236718A1 (en) * 2020-05-20 2021-11-25 Fred Hutchinson Cancer Research Center Anti-fibrotic composition and related methods
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN117126142B (zh) * 2023-08-30 2026-02-10 遵义医科大学珠海校区 杂环类egfr突变抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
DE102004035655A1 (de) * 2004-07-22 2006-02-16 Henkel Kgaa Verfahren zur Herstellung von Mehrphasen-Sticks für die WC-Reinigung
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
ATE489380T1 (de) * 2006-02-10 2010-12-15 Amgen Inc Hydratformen von amg706
BRPI0709917A2 (pt) * 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
CA2723617A1 (en) 2009-11-19
EP2288383A1 (en) 2011-03-02
JP2011520908A (ja) 2011-07-21
JP5699075B2 (ja) 2015-04-08
AU2009246263A1 (en) 2009-11-19
WO2009140549A1 (en) 2009-11-19
US20140243339A1 (en) 2014-08-28
US20110104161A1 (en) 2011-05-05
AU2009246263B2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
JP5699075B2 (ja) 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
JP5142981B2 (ja) 抗ｅｇｆｒ抗体およびｖｅｇｆｒ阻害剤を含む、癌の治療のための組み合わせ
US9133162B2 (en) Substituted quinoline compounds and methods of use
JP2024532374A (ja) Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
CA3172586C (en) IMATINIB AEROSOL COMPOUNDS AND RELATED USES
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
AU2012223639A1 (en) Substituted quinoline compounds and methods of use
KR20070116936A (ko) 혈전증의 치료를 위한 신규 약제학적 조성물
US8975282B2 (en) Substituted pyrazolone compounds and methods of use
WO2013180949A1 (en) Substituted quinoline compounds and methods of use
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
JP2012072140A (ja) 異常な細胞増殖を処置する方法
TWI565702B (zh) 取代的吡唑酮化合物及其使用方法
WO2025157389A1 (en) Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
CN117835978A (zh) 包含tead抑制剂的药物组合及其用于癌症治疗的用途
ES2367872T3 (es) Combinaciones para el tratamiento de cáncer que comprenden un anticuerpo anti-egfr e inhibidores de vegfr.
HK1187259B (en) Substituted quinoline compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal